Search

Albert S Bendelac

from Chicago, IL
Age ~67
Get Report
Also known as:
Al Bendelac, Albert Bender
Phone and address:
1121 53Rd St, Chicago, IL 60615
(773) 643-0888
Related to:
Albert Bender, 67Julien BendelacBana Bendelac, 63
Connected to:
Amiram M Bendel, 66Brandon C Bendel, 32Chad Bendel, 45Julia M Bendel, 42Louise J Bendel, 63Scott A Bendel, 34Adam P Bendele, 46Alison M Bendele, 71Amber M Bendele, 33Anthony W Bendele, 32

Albert Bendelac Phones & Addresses

  • 1121 53Rd St, Chicago, IL 60615 (773) 643-0888
  • 528 Mercer St, Princeton, NJ 08540 (609) 924-5365
  • 8906 Old Georgetown Rd, Bethesda, MD 20814 (301) 564-1402

Publications

Us Patents

Adjuvants And Methods Of Use

View page
US Patent:
7794722, Sep 14, 2010
Filed:
Jun 29, 2007
Appl. No.:
11/771128
Inventors:
Luc Teyton - Del Mar CA, US
Albert Bendelac - Chicago IL, US
Paul B. Savage - Mapleton UT, US
Assignee:
The Scripps Research Institute - La Jolla CA
The University of Chicago - Chicago IL
Brigham Young University - Provo UT
International Classification:
A61K 39/00
A61K 39/38
A61K 45/00
A61K 47/00
A61K 31/70
A01N 43/04
US Classification:
4241841, 4242781, 514 25
Abstract:
Compositions comprising NKT cell agonist compounds and a physiologically acceptable vehicle are provided. Methods of stimulating an NKT cell and enhancing an immune response are also disclosed. Further provided are vaccine preparations comprising NKT cell agonist compounds.

6″-Amino-6″-Deoxygalactosylceramides

View page
US Patent:
7989423, Aug 2, 2011
Filed:
Nov 24, 2009
Appl. No.:
12/625048
Inventors:
Paul B. Savage - Mapleton UT, US
Albert Bendelac - Chicago IL, US
Luc Teyton - Delmar CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
Brigham Young University - Provo UT
The University of Chicago - Chicago IL
International Classification:
A61K 31/7028
A61P 31/04
US Classification:
514 25
Abstract:
This invention relates to galactosylceramide compounds.

Methods Of Activating Nkt Cells

View page
US Patent:
7998739, Aug 16, 2011
Filed:
Sep 2, 2005
Appl. No.:
11/218906
Inventors:
Albert Bendelac - Chicago IL, US
Dapeng Zhou - Chicago IL, US
Luc Teyton - Del Mar CA, US
Paul Savage - Mapleton UT, US
Assignee:
The Scipps Research Institute - La Jolla CA
Brigham Young University - Provo UT
The University of Chicago - Chicago IL
International Classification:
C12N 5/07
A61K 31/70
C07K 14/00
US Classification:
435375, 514 25, 514 54
Abstract:
Provided are methods of activating an NKT cell which include a step of contacting the NKT cell with a sufficient amount of isoglobotrihexosylceramide (iGb3) to induce secretion of a cytokine from the NKT cell, stimulate proliferation of the NKT cell or upregulate expression of a cell surface marker on the NKT cell. Methods of activating an NKT cell population in a subject are also provided.

Modified Α-Galactosyl Ceramides For Staining And Stimulating Natural Killer T Cells

View page
US Patent:
8227581, Jul 24, 2012
Filed:
Apr 9, 2007
Appl. No.:
12/296169
Inventors:
Paul B. Savage - Mapleton UT, US
Luc Teyton - Del Mar CA, US
Albert Bendelac - Chicago IL, US
Assignee:
The Scripps Research Institute - La Jolla CA
The University of Chicago - Chicago IL
Brigham Young University - Provo UT
International Classification:
A61K 39/00
A61K 39/7028
A61K 38/17
C07H 15/04
US Classification:
536 111, 536 179, 514 11, 514 24, 514 25, 4241841
Abstract:
Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.

Method Of Stimulating Nkt With 6″-Amino-6″-Deoxygalactosylceramides

View page
US Patent:
8445272, May 21, 2013
Filed:
Aug 2, 2011
Appl. No.:
13/196631
Inventors:
Paul B. Savage - Mapleton UT, US
Albert Bendelac - Chicago IL, US
Luc Teyton - Delmar CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
The University of Chicago - Chicago IL
Brigham Young University - Provo UT
International Classification:
C12N 5/06
C12N 5/00
A01N 25/00
A61K 31/739
US Classification:
435325, 435372, 514885, 514 25
Abstract:
This invention relates to galactosylceramide compounds.

6"-Amino-6"-Deoxygalactosylceramides

View page
US Patent:
20060264382, Nov 23, 2006
Filed:
Mar 20, 2003
Appl. No.:
10/550165
Inventors:
Paul Savage - Mapleton UT, US
Albert Bendelac - Chicago IL, US
Luc Teyton - Del Mar CA, US
Assignee:
BRIGHAM YOUNG UNIVERSITY - Provo UT
International Classification:
A61K 31/7008
US Classification:
514023000, 536053000
Abstract:
This invention relates to galactosylceramide compounds.

Bacterial Glycolipid Activation Of Cd1D-Restricted Nkt Cells

View page
US Patent:
20080279894, Nov 13, 2008
Filed:
Jan 26, 2006
Appl. No.:
11/814103
Inventors:
Paul B. Savage - Mapleton UT, US
Albert Bendelac - Chicago IL, US
Luc Teyton - Del Mar CA, US
Assignee:
BRIGHAM YOUNG UNIVERSITY - Provo UT
THE UNIVERSITY OF CHICAGO - Chicago IL
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA
International Classification:
A61K 39/02
C12N 5/06
A61K 39/00
US Classification:
4242341, 435375, 4241841
Abstract:
Disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, methods of improving vaccine efficacy, and methods of treating an infection. Also disclosed are methods of promoting tumor rejection, treating cancer, modulating autoimmunity and inhibiting allergen-induced hypersensitivity in subjects. The methods include contacting an NKT cell with a bacterial glycolipid complexed with a CD1 molecule to activate the NKT cell. The bacterial glycolipid may be derived from a member of the Class Alphaproteobacteria.

Adjuvants And Methods Of Use

View page
US Patent:
20110027323, Feb 3, 2011
Filed:
Aug 4, 2010
Appl. No.:
12/850428
Inventors:
Luc Teyton - Del Mar CA, US
Albert Bendelac - Chicago IL, US
Paul B. Savage - Mapleton UT, US
Assignee:
The Scripps Research Institute - La Jolla CA
The University of Chicago - Chicago IL
Brigham Young University - Provo UT
International Classification:
A61K 39/00
A61K 31/7028
C12N 5/071
C12N 5/0783
A61P 37/04
US Classification:
4242771, 514 23, 514 25, 435375, 4241841
Abstract:
Compositions comprising NKT cell agonist compounds and a physiologically acceptable vehicle are provided. Methods of stimulating an NKT cell and enhancing an immune response are also disclosed. Further provided are vaccine preparations comprising NKT cell agonist compounds.
Control profile
Albert S Bendelac from Chicago, IL, age ~67 Get Report